Additionally, the use of SGLT2 inhibitor was associated with lower risk of mortality (HR 0.61; 95% CI 0.39–0.94; P = 0.025), including CV mortality (HR 0.43 [95% CI 0.21–0.86], P = 0.018), but not of MI (HR 1.22 [95% CI 0.72–2.09]; P = 0.461), stroke (HR 1.0 [95% CI 0.75–1.33], P = 0.980), MACE (HR 0.98 [95% CI 0.78–1.23], P = 0.831) or hypoglycemia (HR 0.83 [95% CI 0.51–1.35], P = 0.446) compared to DPP4 inhibitor. This evidence concerns the gene SLC5A2 and Hypoglycemia.